kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers
Autor: | Marta Cruz, Enrique Ramos, Cristina Almirall, Jose María Castellano-Vazquez, Francisco Peñalver, Jose F. Varona, Elena Abarca, Rodrigo Madurga |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Health Personnel 030204 cardiovascular system & hematology Antibodies Viral Antibodies Durability Persistence (computer science) Persistence 03 medical and health sciences 0302 clinical medicine Internal medicine Internal Medicine medicine Humans 030212 general & internal medicine Prospective Studies Prospective cohort study biology business.industry SARS-CoV-2 Immune-response Antibody titer Healthcare Workers COVID-19 Middle Aged Titer Kinetics Healthcare Personnel biology.protein Original Article Female Antibody business Antibody kinetics Month follow up Follow-Up Studies |
Zdroj: | European Journal of Internal Medicine DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria instname |
ISSN: | 1879-0828 |
Popis: | Background The kinetics of the antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated since long-term duration of antibody remains largely unknown, particularly in infected healthcare workers (HCW). Methods Prospective study, evaluating the longitudinal profile of anti-SARS-CoV-2 antibody titers in a random sample of 331 seropositive healthcare workers (HCW) of Spanish Hospitals Group. Serial measurements of serum IgG-anti-SARS-CoV-2 were obtained at baseline (April-May,2020), and in 2 follow-up visits. Linear mixed models were used to investigate antibody kinetics and associated factors. Results A total of 306 seropositive subjects (median age: 44.7years;69.9% female) were included in the final analysis. After a median follow-up of 274 days between baseline and final measurement, 235(76.8%) maintained seropositivity. Antibody titers decreased in 82.0%, while remained stable in 13.1%. Factors associated with stability of antibodies over time included age≥45 years, higher baseline titers, severe/moderate infection and high-grade exposure to COVID-19 patients. In declining profile, estimated mean antibody half-life was 146.3 days(95%CI:138.6–154.9) from baseline. Multivariate models show independent longer durability of antibodies in HCW with high-risk exposure to COVID-19 patients (+14.1 days;95%CI:0.6–40.2) and with symptomatic COVID-19 (+14.1 days;95%CI:0.9–43.0). The estimated mean time to loss antibodies was 375(95% CI:342–408) days from baseline. Conclusions We present the first study measuring the kinetics of antibody response against SARS-CoV-2 in HCW beyond 6 months. Most participants remained seropositive after 9 months but presented a significant decline in antibody-titers. Two distinct antibody dynamic profiles were observed (declining vs. stable). Independent factors associated with longer durability of antibodies were symptomatic infection and higher exposure to COVID-19 patients. post-print 1262 KB |
Databáze: | OpenAIRE |
Externí odkaz: |